Connor, Clark & Lunn Investment Management Ltd. Eagle Pharmaceuticals, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$25.06 - $34.09 $233,283 - $317,343	9,309 New	9,309 $264,000
Q3 2020 Nov 12, 2020	SELL	$37.02 - $51.28 $194,392 - $269,271	-5,251 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$43.24 - $55.02 $43,196 - $54,964	-999 Reduced 15.98%	5,251 $252,000
Q4 2019 Feb 12, 2020	SELL	$54.32 - $64.31 $1.33 Million - $1.57 Million	-24,483 Reduced 79.66%	6,250 $376,000
Q3 2019 Nov 13, 2019	SELL	$53.25 - $59.98 $435,851 - $490,936	-8,185 Reduced 21.03%	30,733 $1.74 Million
Q2 2019 Aug 07, 2019	BUY	$46.61 - $58.45 $6,991 - $8,767	150 Added 0.39%	38,918 $2.17 Million
Q1 2019 May 08, 2019	BUY	$38.66 - $51.82 $60,889 - $81,616	1,575 Added 4.23%	38,768 $1.96 Million
Q4 2018 Feb 12, 2019	SELL	$36.72 - $67.73 $113,832 - $209,963	-3,100 Reduced 7.69%	37,193 $1.5 Million
Q3 2018 Nov 13, 2018	BUY	$66.65 - $83.86 $19,995 - $25,158	300 Added 0.75%	40,293 $2.79 Million
Q2 2018 Aug 02, 2018	SELL	$51.25 - $76.62 $329,640 - $492,819	-6,432 Reduced 13.85%	39,993 $3.03 Million
Q1 2018 May 14, 2018	BUY	$52.16 - $66.86 $594,624 - $762,204	11,400 Added 32.55%	46,425 $2.45 Million
Q4 2017 Feb 09, 2018	BUY	$49.6 - $60.87 $631,160 - $774,570	12,725 Added 57.06%	35,025 $1.87 Million
Q3 2017 Nov 14, 2017	BUY	$46.62 - $60.36 $1.04 Million - $1.35 Million	22,300	22,300 $1.33 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account